重组人血小板生成素治疗难治性特发性血小板减少性紫癜临床观察  

Clinical study on recombinant human thrombopoietin in the treatment of refractory idiopathic thrombocytopenic purpura

作　　者：张晓丽[1] 刘延方[1] 孙慧[1] 谢新生[1] 姜中兴[1] 孙玲[1] 万鼎铭[1] 刘林湘[1] 

机构地区：[1]郑州大学第一附属医院血液科,450052

出　　处：《中国实用医刊》2010年第7期17-18,共2页Chinese Journal of Practical Medicine

摘　　要：目的 观察重组人血小板生成素(rhTPO)治疗慢性难治性特发性血小板减少性紫癜(ITP)的临床疗效及不良反应.方法 24例慢性难治性ITP患者皮下注射rhTPO 300 IU/(kg·d),疗程14 d或血小板＞100×109/L后停药.结果 24例患者rhTPO治疗后,显效12例,有效5例,用药前血小板平均值为(10±5)×109/L,治疗后血小板计数的升高的最高值为(129±97)×109/L,与用药前比较差异有统计学意义(t=5.822,P＜0.01).多数患者对药物耐受良好.结论 rhTPO治疗慢性难治性ITP具有良好的疗效,不良反应轻微.Objective To observe the efficacy and toxicity of recombinant human thrombopoietin (rhTPO)in the treatment of chronic refractory idiopathic thrombocytopenic purpura(ITP).Methods Twenty- four patients with chronic ITP were administered with rhTPO subcutaneously at 300 IU/(kg · d)for 14 days or until the platelet count ＞ 100 × 109/L.Results Out of 24 patients with ITP, 12 cases showed significant response and 5 cases showed good response to the treatment with rhTPO.The peak platelet count after treatment was(129 ± 97)× 109/L, significantly higher than the mean platelet count [(10 ±5)× 109/L]before treatment(t = 5.822, P ＜0.01).The agent was well tolerated in most patients.Conclusions rhTPO exerts satisfactory efficacy in the treatment of chronic ITP with mild side effects.

关 键 词：血小板生成素 特发性血小板减少性 紫癜 治疗 

分 类 号：R554.6[医药卫生—血液循环系统疾病]